Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C

Pierluigi Toniutto, Carlo Fabris, Edmondo Falleti, Annarosa Cussigh, Elisabetta Fontanini, Davide Bitetto, Ezio Fornasiere, Rosalba Minisini, Tullia De Feo, Francesca Marangoni, Mario Pirisi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background/Aims: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, being a putative steatogenic factor, may promote liver fibrosis progression in patients with chronic hepatitis C. This study aimed to verify the role of recipient MTHFR polymorphism in favouring graft fibrosis progression in patients with recurrent HCV after orthotopic liver transplantation (OLT). Methods: We studied 63 such patients, followed for >1 year. MTHFR allelic variants were determined by a polymerase chain reaction/restriction fragment length polymorphism method. Results: Recipients carrying the TT genotype had more frequently, 1-year post-OLT, homocysteine serum levels >23 μmol/L (P <0.05), serum triglycerides >180 mg/dL (P <0.02) and de novo diabetes mellitus (P 2 was performed by stratifying the recipients as follows: (a) patients with donor age ≤45 years, (b) patients with donor age >45 and C/* genotype, and (c) patients with donor age ≤45 years and TT genotype. A significant linear trend was observed, with increasing frequencies as follows: (a) 8/37, (b) 10/19 and (c) 6/7 (P = 0.0005). Conclusion: The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalLiver International
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Hepatitis C
Liver Cirrhosis
Genotype
Liver Transplantation
Tissue Donors
Homocysteine
Chronic Hepatitis C
Restriction Fragment Length Polymorphisms
Fibrosis
Transplants
Polymerase Chain Reaction
Serum

Keywords

  • Hepatitis C
  • Liver fibrosis
  • Liver transplantation
  • MTHFR gene

ASJC Scopus subject areas

  • Hepatology

Cite this

Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. / Toniutto, Pierluigi; Fabris, Carlo; Falleti, Edmondo; Cussigh, Annarosa; Fontanini, Elisabetta; Bitetto, Davide; Fornasiere, Ezio; Minisini, Rosalba; De Feo, Tullia; Marangoni, Francesca; Pirisi, Mario.

In: Liver International, Vol. 28, No. 2, 02.2008, p. 257-263.

Research output: Contribution to journalArticle

Toniutto, P, Fabris, C, Falleti, E, Cussigh, A, Fontanini, E, Bitetto, D, Fornasiere, E, Minisini, R, De Feo, T, Marangoni, F & Pirisi, M 2008, 'Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C', Liver International, vol. 28, no. 2, pp. 257-263. https://doi.org/10.1111/j.1478-3231.2007.01591.x
Toniutto, Pierluigi ; Fabris, Carlo ; Falleti, Edmondo ; Cussigh, Annarosa ; Fontanini, Elisabetta ; Bitetto, Davide ; Fornasiere, Ezio ; Minisini, Rosalba ; De Feo, Tullia ; Marangoni, Francesca ; Pirisi, Mario. / Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. In: Liver International. 2008 ; Vol. 28, No. 2. pp. 257-263.
@article{3b9927e2e99b49f3bdb3d728bd1cddcf,
title = "Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C",
abstract = "Background/Aims: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, being a putative steatogenic factor, may promote liver fibrosis progression in patients with chronic hepatitis C. This study aimed to verify the role of recipient MTHFR polymorphism in favouring graft fibrosis progression in patients with recurrent HCV after orthotopic liver transplantation (OLT). Methods: We studied 63 such patients, followed for >1 year. MTHFR allelic variants were determined by a polymerase chain reaction/restriction fragment length polymorphism method. Results: Recipients carrying the TT genotype had more frequently, 1-year post-OLT, homocysteine serum levels >23 μmol/L (P <0.05), serum triglycerides >180 mg/dL (P <0.02) and de novo diabetes mellitus (P 2 was performed by stratifying the recipients as follows: (a) patients with donor age ≤45 years, (b) patients with donor age >45 and C/* genotype, and (c) patients with donor age ≤45 years and TT genotype. A significant linear trend was observed, with increasing frequencies as follows: (a) 8/37, (b) 10/19 and (c) 6/7 (P = 0.0005). Conclusion: The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion.",
keywords = "Hepatitis C, Liver fibrosis, Liver transplantation, MTHFR gene",
author = "Pierluigi Toniutto and Carlo Fabris and Edmondo Falleti and Annarosa Cussigh and Elisabetta Fontanini and Davide Bitetto and Ezio Fornasiere and Rosalba Minisini and {De Feo}, Tullia and Francesca Marangoni and Mario Pirisi",
year = "2008",
month = "2",
doi = "10.1111/j.1478-3231.2007.01591.x",
language = "English",
volume = "28",
pages = "257--263",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C

AU - Toniutto, Pierluigi

AU - Fabris, Carlo

AU - Falleti, Edmondo

AU - Cussigh, Annarosa

AU - Fontanini, Elisabetta

AU - Bitetto, Davide

AU - Fornasiere, Ezio

AU - Minisini, Rosalba

AU - De Feo, Tullia

AU - Marangoni, Francesca

AU - Pirisi, Mario

PY - 2008/2

Y1 - 2008/2

N2 - Background/Aims: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, being a putative steatogenic factor, may promote liver fibrosis progression in patients with chronic hepatitis C. This study aimed to verify the role of recipient MTHFR polymorphism in favouring graft fibrosis progression in patients with recurrent HCV after orthotopic liver transplantation (OLT). Methods: We studied 63 such patients, followed for >1 year. MTHFR allelic variants were determined by a polymerase chain reaction/restriction fragment length polymorphism method. Results: Recipients carrying the TT genotype had more frequently, 1-year post-OLT, homocysteine serum levels >23 μmol/L (P <0.05), serum triglycerides >180 mg/dL (P <0.02) and de novo diabetes mellitus (P 2 was performed by stratifying the recipients as follows: (a) patients with donor age ≤45 years, (b) patients with donor age >45 and C/* genotype, and (c) patients with donor age ≤45 years and TT genotype. A significant linear trend was observed, with increasing frequencies as follows: (a) 8/37, (b) 10/19 and (c) 6/7 (P = 0.0005). Conclusion: The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion.

AB - Background/Aims: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, being a putative steatogenic factor, may promote liver fibrosis progression in patients with chronic hepatitis C. This study aimed to verify the role of recipient MTHFR polymorphism in favouring graft fibrosis progression in patients with recurrent HCV after orthotopic liver transplantation (OLT). Methods: We studied 63 such patients, followed for >1 year. MTHFR allelic variants were determined by a polymerase chain reaction/restriction fragment length polymorphism method. Results: Recipients carrying the TT genotype had more frequently, 1-year post-OLT, homocysteine serum levels >23 μmol/L (P <0.05), serum triglycerides >180 mg/dL (P <0.02) and de novo diabetes mellitus (P 2 was performed by stratifying the recipients as follows: (a) patients with donor age ≤45 years, (b) patients with donor age >45 and C/* genotype, and (c) patients with donor age ≤45 years and TT genotype. A significant linear trend was observed, with increasing frequencies as follows: (a) 8/37, (b) 10/19 and (c) 6/7 (P = 0.0005). Conclusion: The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion.

KW - Hepatitis C

KW - Liver fibrosis

KW - Liver transplantation

KW - MTHFR gene

UR - http://www.scopus.com/inward/record.url?scp=38849203079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849203079&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2007.01591.x

DO - 10.1111/j.1478-3231.2007.01591.x

M3 - Article

C2 - 17900242

AN - SCOPUS:38849203079

VL - 28

SP - 257

EP - 263

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 2

ER -